PMLiVE5d
GSK’s investigational antibiotic granted FDA priority review for urinary tract infections
GSK’s new drug application for its investigational oral antibiotic gepotidacin has been accepted for priority review by the ...
PMLiVE6d
Amgen shares positive late-stage results for Uplizna in generalised myasthenia gravis
Amgen has shared positive top-line results from a late-stage trial of its B cell-depleting therapy Uplizna (inebilizumab-cdon ...
PMLiVE7d
Inizio Medical appoints Matt Wadyka as president, US medical affairs
Inizio Medical has announced the appointment of Matt Wadyka as president, US medical affairs. In this newly created role, ...
PMLiVE14d
Merck’s Keytruda shows promise as perioperative head and neck cancer treatment
Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...
PMLiVE7d
J&J’s nipocalimab shows sustained disease control in adolescents with generalised myasthenia gravis
Johnson & Johnson’s (J&J) investigational FcRn blocker nipocalimab has demonstrated sustained disease control in adolescents with the rare autoimmune disease generalised myasthenia gravis (gMG), ...
PMLiVE19d
Bristol Myers Squibb’s Opdivo regimen granted FDA approval in NSCLC
Bristol Myers Squibb’s Opdivo (nivolumab) has been approved by the US Food and Drug Administration (FDA) as part of a perioperative treatment regimen for adults with non-small cell lung cancer (NSCLC) ...
PMLiVE5d
Sex, Gender, and the Brain: The Women’s Brain Foundation and Medscape Education Announce Groundbreaking Learning Centre
LONDON–(BUSINESS WIRE)–The Women’s Brain Foundation (WBF), the global pioneer that has advanced the inclusion of sex- and gender-based evidence-generation in all research, drug development, and ...
PMLiVE9d
Pfizer shares positive phase 3 results for Talzenna combination in prostate cancer
Pfizer has announced positive overall survival (OS) results from a late-stage study of its prostate cancer combination treatment. The phase 3 TALAPRO-2 trial has been evaluating the drugmaker’s PARP ...
PMLiVE12d
Roche’s Itovebi combination granted FDA approval for advanced breast cancer
Roche’s PI3K inhibitor Itovebi (inavolisib) has been approved by the US Food and Drug Administration (FDA) as part of a combination treatment for advanced breast cancer. The drug has been authorised ...
PMLiVE12d
Eli Lilly and insitro collaborate to advance new treatments for metabolic diseases
Eli Lilly has partnered with insitro to advance new treatments for metabolic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD). The new drugs developed under the ...
PMLiVE13d
PM Society Awards 2025 open for entries
You can now start working on your entries and don’t forget to get them to us by Thursday 14 November by midnight to qualify for our early bird pricing. Entry deadline is Thursday 21 November and a ...
PMLiVE14d
Behavioural Data Offering from Medscape Global
See more about this new insights product, Medscape AffinityTM, which offers unparalleled insights into the online behaviour of 13M+ HCPs to help you make fully informed decisions around your brand and ...